GlaxoSmithKline (GSK) has said that its cycle-to-work scheme was more popular than its health screening benefit, after it launched the two salary sacrifice perks in June.
Out of the pharmaceutical firm's 18,500-strong workforce, 427 employees took up the cycle-to-work scheme, while 270 staff opted for health screening.
Harsha Modha, director of benefit programmes at GlaxoSmithKline, said: "Health screening is not always appropriate for everybody."
The company intends to monitor take up and is also considering offering cheaper health benefits, such as blood and cholesterol checks.